Marker beacon

Groundbreaking DNA-based Solution Attempts to Tackle Soaring Emergency Room Visits Linked to Cannabis Consumption

Retrieved on: 
Monday, June 5, 2023

BURBANK, Calif., June 5, 2023 /PRNewswire/ -- Endocanna Health ("Endocanna"), the industry leader in endocannabinoid system genomic testing, announces the issuance of a first-of-its-kind U.S. patent for its DNA test that brings to healthcare hyper-personalized cannabinoid therapies based on user genetics. The test helps consumers potentially avoid cannabis products that may cause negative health effects such as cannabis-induced psychosis and rapid heart rate.

Key Points: 
  • The test helps consumers potentially avoid cannabis products that may cause negative health effects such as cannabis-induced psychosis and rapid heart rate.
  • Endocanna's patented technology reduces adverse effects
    Emergency room visits resulting from cannabis consumption have skyrocketed where the plant is legal.
  • In California, cannabis-related emergency care visits among those aged 65 and older rose 1,804% from 2005 to 2019 .
  • Such visits increased threefold in Colorado between 2012 and 2016 and increased fivefold in Ontario from 2003 to 2017.

GeneType featured on U.S. National TV to raise Breast Cancer Awareness

Retrieved on: 
Tuesday, May 23, 2023

In the segment Dr. Carolynn Young and Dr. Joel Evans discuss factors that influence breast cancer risk and the clinical utility of geneType for Breast Cancer.

Key Points: 
  • In the segment Dr. Carolynn Young and Dr. Joel Evans discuss factors that influence breast cancer risk and the clinical utility of geneType for Breast Cancer.
  • Dr. Carolynn Young promotes our geneType test for Breast Cancer as a great tool for women wanting to know and reduce their risk of developing breast cancer.
  • Dr. Evans commented that he believes “the best way to look at breast cancer risk is through the geneType collection kit.” GeneType for Breast Cancer integrates over 300 genetic markers for breast cancer as well as clinical and familial factors to give a comprehensive and individualized risk prediction score.
  • Find out your underlying genetic risk of developing breast cancer with geneType - so that you and your doctor can have proactive discussions about your health, which could include adapting your screening intervals and types, and making lifestyle modifications to reduce your risk of breast cancer.

23andMe Releases New Report Revealing Likelihood of Developing Lupus

Retrieved on: 
Tuesday, May 9, 2023

The report, which is powered by data from consenting 23andMe research participants, is available for its 23andMe+ members.

Key Points: 
  • The report, which is powered by data from consenting 23andMe research participants, is available for its 23andMe+ members.
  • As we recognize Lupus Awareness Month , 23andMe’s new report includes helpful insight into a customer’s likelihood of developing this hard to diagnose autoimmune disease.
  • Understanding one’s genetic likelihood of developing the disease could help them better understand their overall risk.”
    23andMe’s new report uses machine learning techniques to estimate an individual’s likelihood of being diagnosed with lupus.
  • Note that 23andMe’s report on lupus can provide users with helpful information on their estimated genetic likelihood of being diagnosed with the condition.

Plantis Licenses Two of Canonic's Proprietary Cannabis Varieties to Expand its Offerings in the Israeli Market

Retrieved on: 
Tuesday, May 2, 2023

The two new varieties were developed by Canonic using proprietary sets of novel genetic markers targeting unique differentiation factors.

Key Points: 
  • The two new varieties were developed by Canonic using proprietary sets of novel genetic markers targeting unique differentiation factors.
  • The new medical cannabis products made from these two varieties, will expand Plantis' product offering and cater to a broader range of customers in Israel.
  • Plantis is a medical cannabis company with the aim of improving, enhancing, and refining the treatment options with medical cannabis.
  • We look forward to continuing to expand our relationship with Plantis over the coming years."

Does our DNA really determine our intelligence and health?

Retrieved on: 
Sunday, April 23, 2023

In a recent article from Nature Genetics_, scientists raise concerns over the social impacts of recent advances in genomics - i.e.

Key Points: 
  • In a recent article from Nature Genetics_, scientists raise concerns over the social impacts of recent advances in genomics - i.e.
  • the study of genomes, or in other words, the genetic material of an individual or species.
  • In passages bringing to mind the dystopian sci-fi film Gattaca, they describe a near future in which one’s DNA could foretell one’s physical and intellectual abilities and near-perfect children be conceived in vitro.

What is a GWAS?

    • The markers can be considered as small flags planted along the genome, each flag having two possible colours (the alleles).
    • The idea behind GWAS is that an association between a marker and a trait allows for the detection of genetic factors independently of environmental factors.

A new market

    • 23andMe managed to keep its doors open by changing its approach and collecting DNA to map out the geographical origins of people’s ancestors.
    • An important part of these DNAs has been made available to scientific teams, allowing them to perform and publish GWAS on huge samples.
    • Four years later, a study based on 3 million individuals found the number of genetic factors multiplied by 4.

The mistaken assumptions behind Polygenic Risk Scores

    • The problem is that these conclusions are based on erroneous assumptions and misinterpretation of associations between the traits to be predicted and genetic markers.
    • Indeed, Polygenic Risk Scores are specifically based on assumptions put forward in 1965 by Douglas Scott Falconer.

Misinterpretations of the GWAS studies

    • Another problem is that Polygenic Risk Scores are based on a flawed interpretation of the GWAS studies.
    • For if the link between a trait and genetic marker could indeed indicate a genetic factor, this remains to be confirmed by subsequent family and functional studies.
    • For example, a GWAS study comparing people in France who consume salted butter with those who consume unsalted butter would show a large number of genetic markers associated with this trait.

Sociological consequences

    • The IQ variable was originally thought out as a tool to measure the adequacy of a child to a given school programme.
    • It is not a universal and timeless measure of cognitive abilities, or even of intelligence.

Ethical implications

    • In his presidential address to the American Society of Human Genetics in 2015 [https://pubmed.ncbi.nlm.nih.gov/26942276/ref], geneticist Neil Risch mischievously commented the approach and conclusions.
    • He calculated the scores of Craig Venter (pioneer of human genome sequencing) and James Watson (co-discoverer of the DNA structure).
    • Risch humorously concluded that a below-average score was enough to land a Nobel Prize or the Medal of Science.

A flawed genetic model

    • But they merely raise ethical issues, failing to stress, in the process, that the root of the problem remains an inappropriate genetic model and the misinterpretation of associations with genetic markers.
    • Yet to deny the validity of genetic predictions of complex traits is not to deny the effect of genetic factors on these traits.

Foundational LCD Covers Select mdx for Prostate Cancer

Retrieved on: 
Wednesday, April 19, 2023

IRVINE, CA, and HERSTAL, BELGIUM – April 19, 2023 – MDxHealth SA (NASDAQ/Euronext: MDXH), a commercial-stage precision diagnostics company, received notice that its Select mdx for Prostate Cancer test has successfully completed a rigorous technical assessment process with the Molecular Diagnostics Services (MolDX) Program developed by Palmetto GBA.

Key Points: 
  • IRVINE, CA, and HERSTAL, BELGIUM – April 19, 2023 – MDxHealth SA (NASDAQ/Euronext: MDXH), a commercial-stage precision diagnostics company, received notice that its Select mdx for Prostate Cancer test has successfully completed a rigorous technical assessment process with the Molecular Diagnostics Services (MolDX) Program developed by Palmetto GBA.
  • Select mdx will be reimbursed throughout the U.S. for Medicare patients who meet coverage conditions under the foundational Local Coverage Determination (LCD) for Molecular Biomarkers to Risk-Stratify Patients at Increased Risk for Prostate Cancer.
  • We look forward to expanding the availability of our test to current and new customers and to patients entering the diagnostic pathway of prostate cancer.
  • We believe our pre-biopsy Select mdx test, coupled with our post-biopsy Confirm mdx® and Genomic Prostate Score (formerly Oncotype DX GPS) tests, provides the most comprehensive and clinically actionable pathway for urologists and patients.”

Illegal logging in Africa is a threat to security

Retrieved on: 
Wednesday, April 19, 2023

African countries are estimated to lose US$17 billion each year to illegal logging.

Key Points: 
  • African countries are estimated to lose US$17 billion each year to illegal logging.
  • Illegal logging is most prevalent in the continent’s tropical rainforests.
  • Illegal logging has negative environmental effects that weaken human security.
  • Firstly, illegal logging amplifies threats posed by organised criminal groups and violent extremist organisations.

The knock-on effects

    • It identifies and tracks criminal networks, state-embedded actors, foreign actors and “mafia-style” armed groups that are locally well known and that control territory.
    • The work of these groups has several knock-on effects.
    • Violent extremism and insurgency: The illicit timber trade fuels conflict and instability by providing resources for violent actors.
    • In Senegal, the Movement of Democratic Forces of Casamance recently funded its insurgency through the illicit logging of rosewood.

Solutions

    • Guinea-Bissau, the DRC and Kenya have controversially ended moratoria on logging.
    • It’s easy to get around a moratorium when state security and justice systems do not operate transparently.
    • A moratorium can even harden criminal networks without addressing the corruption and livelihood challenges that facilitate illegal logging.
    • The Kenya Forestry Service is pioneering an app for officers to use satellite data in community-based initiatives.

Bridging gaps

    • For example, in Gabon, civil society has pressured the government for greater transparency in logging contracts.
    • Civil society also builds economic resilience to illegal logging.
    • In Tanzania and the DRC, civil society has enhanced community control over land management and made legal livelihoods in the logging sector more feasible.

Key takeaways

    • External oversight is a key part of countering illegal logging.
    • It works best where civil society is strong.
    • Inspectors general, specialised prosecutors and independent anti-corruption bodies can help expose the kingpins organising illegal operations.

MyOme Announces Publication of a Validated Cross-Ancestry Polygenic Risk Score for Breast Cancer

Retrieved on: 
Wednesday, February 22, 2023

MENLO PARK, Calif., Feb. 22, 2023 /PRNewswire/ -- Myome, Inc., a clinical whole genome platform analysis company and a leader in the development of polygenic risk scores with relevance across multiple ancestries, today announced the publication in JCO Precision Oncology of a validation study for its cross-ancestry, integrated risk score. In the study, data from over 130,000 women demonstrated that MyOme's cross-ancestry, integrated risk score (caIRS) significantly improved breast cancer risk prediction over the common clinical measurement, Tyrer-Cuzick (T-C) alone.

Key Points: 
  • In the study, data from over 130,000 women demonstrated that MyOme's cross-ancestry, integrated risk score (caIRS) significantly improved breast cancer risk prediction over the common clinical measurement, Tyrer-Cuzick (T-C) alone.
  • To address this issue, MyOme has developed a cross-ancestry, integrated polygenic risk score (caIRS) for breast cancer.
  • The caIRS integrates hundreds of thousands of genetic markers across the genome to support sophisticated disease and ancestral models and combines a cross-ancestry polygenic risk score with a clinical estimator for breast cancer risk (T-C) to provide a more comprehensive risk assessment.
  • The authors of the study assessed the association between the caIRS and breast cancer risk in two validation cohorts of more than 130,000 women.

Canonic Successfully Launched Six Second-Generation Cannabis Products with Higher THC and Rich Terpene Profiles

Retrieved on: 
Tuesday, February 21, 2023

REHOVOT, Israel, Feb. 21, 2023 /PRNewswire/ -- Canonic Ltd., focused on the development of medical grade cannabis products and a wholly owned subsidiary of Evogene Ltd. (Nasdaq: EVGN) (TASE: EVGN), today announced the completion of its launch of six second-generation hybrid cannabis products in Israel. The design and development of these new cannabis products leveraged Evogene's GeneRator AI  tech-engine to select desirable characteristics such as THC (tetrahydrocannabinol) content and certain terpene profiles.

Key Points: 
  • The design and development of these new cannabis products leveraged Evogene's GeneRator AI tech-engine to select desirable characteristics such as THC (tetrahydrocannabinol) content and certain terpene profiles.
  • Canonic's second generation products are characterized by high levels of THC, the primary psychoactive ingredient in cannabis, at 23% and above; the highest THC percentage allowed in Israel being 24.4%.
  • The six new products released into the market in Israel are named: Synergy (THC 24%), Combo (THC 24%), Mosaic (THC 23%), Two Stars (THC 24.2%), Mash Kush (THC 24.4%) and Blend Kush (THC 23.8%).
  • The new products were developed through breeding programs carried out by Canonic in parallel to the release in 2021 of Canonic's first-generation two products: G200 (THC 19%) & G150 (THC 18%).

Deka Biosciences Receives FDA Clearance of DK210 (EGFR) Investigational New Drug Application

Retrieved on: 
Monday, January 30, 2023

GERMANTOWN, Md., Jan. 30, 2023 /PRNewswire/ -- Deka Biosciences ("Deka"), a biotech company focused on developing novel cytokine therapies to treat cancer and inflammatory diseases, today announced that the U.S. Food and Drug Administration (FDA) has completed its review of the investigational new drug (IND) application for DK210 (EGFR) and concluded that Deka may proceed with a Phase 1 clinical trial in the United States.

Key Points: 
  • GERMANTOWN, Md., Jan. 30, 2023 /PRNewswire/ -- Deka Biosciences ("Deka"), a biotech company focused on developing novel cytokine therapies to treat cancer and inflammatory diseases, today announced that the U.S. Food and Drug Administration (FDA) has completed its review of the investigational new drug (IND) application for DK210 (EGFR) and concluded that Deka may proceed with a Phase 1 clinical trial in the United States.
  • "Obtaining FDA clearance for our company's first program to start clinical trials is a significant achievement," said Dr. John Mumm, CEO and co-founder of Deka.
  • "We are excited to move forward with the clinical development of DK210 (EGFR) and the potential it holds for positively impacting the lives of many cancer patients."
  • DK210 (EGFR) is the first of several experimental therapeutics developed as part of Deka's platform of molecules.